Bulletin
Investor Alert

New York Markets Open in:

Nov. 22, 2019, 12:02 p.m. EST

NetworkNewsBreaks - Replimune Group, Inc. (US: REPL) Secures $80 Million in Underwritten Public Offering

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Replimune Group Inc. (REPL)

or Cancel Already have a watchlist? Log In

/zigman2/quotes/203971249/composite REPL +2.15%

Nov 22, 2019 (NetworkNewsWire via COMTEX) -- Replimune Group /zigman2/quotes/203971249/composite REPL +2.15% , a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic(TM) platform, has closed an underwritten public offering of 3,678,031 shares of its common stock at a public offering price of $13.61 per share. According to the update, Replimune also, in addition, and in lieu of common stock, closed a public offering of pre-funded warrants to purchase 2,200,000 shares of its common stock at a purchase price of $13.6099 per pre-funded warrant, which equals the public offering price per share of the common stock less the $0.0001 per share exercise price of each pre-funded warrant. Replimune Group secured approximately $80 million in gross proceeds from the offering. Replimune has granted the underwriters a 30-day option to purchase up to an additional 881,704 shares of its common stock at the public offering price. ROTH Capital Partners acted as co-manager for the offering.

To view the full press release, visit http://nnw.fm/fZu3I

About Replimune Group, Inc.

Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer. Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of the immune response to the tumor antigens released. Replimune's Immulytic(TM) platform is designed to maximize systemic immune activation, in particular to tumor neoantigens, through robust viral-mediated immunogenic tumor cell killing and the delivery of optimal combinations of immune-activating proteins to the tumor and draining lymph nodes. For more information, please visit www.Replimune.com .

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today's market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text "STOCKS" to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork .

COMTEX_357613357/2557/2019-11-22T12:01:33

/zigman2/quotes/203971249/composite
US : U.S.: Nasdaq
$ 19.99
+0.42 +2.15%
Volume: 107,266
Nov. 25, 2022 1:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$994.29 million
Rev. per Employee
N/A
loading...
/zigman2/quotes/203971249/composite
US : U.S.: Nasdaq
$ 19.99
+0.42 +2.15%
Volume: 107,266
Nov. 25, 2022 1:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$994.29 million
Rev. per Employee
N/A
loading...

This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.